Results · Apr-Jun 2026 · filed 12 Aug 2026
Bal Pharma Q1 FY27 results
Sales grew 35% to ₹88.6 crore from ₹65.9 crore in Apr-Jun 2025.
Operating profit grew 31% to ₹7.9 crore, an operating margin of 9.0% (down 0.2 points from a year ago).
Net profit grew 446% to ₹1.1 crore from ₹0.21 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +5%, net profit −68%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 88.6 | 65.9 | +35% |
| Operating profit (EBITDA) | 7.9 | 6.1 | +31% |
| Operating margin | 9.0% | 9.2% | −0.2 pts |
| Net profit | 1.1 | 0.2 | +446% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
Filings that week
- 13 Aug 2026Newspaper Publications - Unaudited Financial Results 30Th June 2026 And IEPF Notice
- 12 Aug 2026Financial Result For The Quarter End 30Th June 2026
- 12 Aug 2026Board Meeting Outcome for Outcome Of Board Meeting Held On Wednesday, August 12 2026
- 10 Aug 2026Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
- 10 Aug 2026Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.